40% of ulcerative colitis patients in clinical trial reached remission with Abbvie drug
Skyrizi (risankizumab), initially approved to treat Crohn's disease, psoriatic arthritis and psoriasis, has achieved clinical remission in 40% of patients with ulcerative colitis.
Source: beckershospitalreview.com